Fadi Al Akhrass, MD
Infectious Disease · Pikeville, KYNPI 1245557222
Payments from drug & device makers
Across 574 payments — averaging $585.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$155K
- Gilead$136K
- Shionogi Inc$28K
- Madrigal Pharmaceuticals$14K
- Merck$377
- Insmed, Inc.$367
- plus $2K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 195 | $155,315 |
| Gilead | 202 | $135,822 |
| Shionogi Inc | 25 | $28,335 |
| Madrigal Pharmaceuticals | 17 | $14,190 |
| Merck | 20 | $377 |
| Insmed, Inc. | 26 | $367 |
| Amgen | 21 | $355 |
| Philips North America LLC | 2 | $157 |
| Boehringer Ingelheim | 8 | $148 |
| Melinta Therapeutics, LLC | 10 | $144 |
| La Jolla Pharmaceutical Company | 7 | $131 |
| Abbott | 7 | $126 |
| Boston Scientific | 2 | $98 |
| Corcept Therapeutics | 5 | $85 |
| AstraZeneca(2 entities) | 3 | $70 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $62 |
| Lilly USA, LLC | 3 | $55 |
| Nuwellis, Inc. | 1 | $48 |
| Medtronic | 2 | $39 |
| Novartis | 2 | $39 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| GSK | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $17 |
| CSL Behring | 1 | $17 |
| Pfizer | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| GE HealthCare | 1 | $11 |
How this compares
$336,191 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Pikeville
- Faisal KhanPikeville$1K
- Julio RamirezLouisville$18.6M
- Richard GreenbergLexington$18M
- Forest ArnoldLouisville$4.1M
- David DoughertyLexington$512K
- Paul SchulzLouisville$343K
- Martin GnoniLouisville$204K
- Charles RoseLexington$171K
- Tariq MehmoodLouisville$75K
- Wajdi KfouryCorbin$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.